Rapid Micro Biosystems Reports 11.1% Revenue Growth but Increased Net Loss in Q1 2026

Rapid Micro Biosystems, Inc. reported its financial results for the first quarter of 2026, revealing a total revenue of $8.0 million, an increase of 11.1% from $7.2 million in the same period last year. The growth was primarily driven by a 36.0% rise in product revenue, which reached $5.6 million, attributed to increased system placements and higher consumable shipment volumes. However, service revenue declined by 21.9% to $2.4 million, largely due to a decrease in validation revenue, which typically lags behind system placements.

The company's net loss for the quarter was $14.3 million, compared to a loss of $11.3 million in the prior year, marking a 26.7% increase in losses. This increase was influenced by higher operating expenses, which rose by 17.9% to $14.2 million, driven by increased costs in sales and marketing, as well as general and administrative expenses. Research and development expenses decreased slightly by 7.3%, reflecting a reduction in headcount-related costs.

Operationally, Rapid Micro Biosystems placed six Growth Direct systems during the quarter, a 100% increase from three systems in the same period last year, bringing the cumulative total to 196 systems. The company also reported that over 40% of its customers have purchased systems for multiple sites, indicating a growing adoption of its technology. The recurring revenue from consumables and service contracts accounted for 63.3% of total revenue, up from 55.1% in the previous year, highlighting the increasing reliance on ongoing sales from existing customers.

In terms of liquidity, the company had cash and cash equivalents of $13.8 million and short-term investments of $9.1 million as of March 31, 2026. Despite the losses, management believes that existing cash reserves and additional borrowing capacity under a loan agreement will be sufficient to fund operations for at least the next twelve months. The company is also exploring growth opportunities through its partnership with MilliporeSigma, which includes a distribution agreement aimed at expanding market reach and enhancing operational efficiencies.

Looking ahead, Rapid Micro Biosystems aims to increase customer adoption of its Growth Direct platform and expand its market presence. The company plans to invest in sales and marketing initiatives to enhance customer engagement and improve the efficiency of its sales team. However, it acknowledges that achieving positive cash flow and profitability will depend on successfully navigating market conditions and executing its growth strategy.